Q1 Earnings Estimate for Celcuity Issued By Leerink Partnrs

Celcuity Inc. (NASDAQ:CELC) – Equities research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Celcuity in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($0.83) per share for the quarter. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share. Leerink Partnrs also issued estimates for Celcuity’s Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.09) EPS, FY2025 earnings at ($3.77) EPS, FY2026 earnings at ($3.33) EPS and FY2027 earnings at $0.63 EPS.

CELC has been the subject of several other research reports. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research note on Friday, November 15th. Needham & Company LLC lifted their target price on shares of Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, February 6th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $30.17.

Celcuity Stock Down 3.1 %

CELC opened at $11.87 on Monday. The firm has a market capitalization of $440.73 million, a P/E ratio of -4.55 and a beta of 0.73. Celcuity has a one year low of $10.35 and a one year high of $22.19. The company has a fifty day moving average price of $12.30 and a 200-day moving average price of $14.35. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36.

Institutional Investors Weigh In On Celcuity

Several institutional investors have recently bought and sold shares of CELC. nVerses Capital LLC purchased a new position in Celcuity in the 3rd quarter worth approximately $33,000. Prospera Private Wealth LLC bought a new position in shares of Celcuity in the third quarter worth approximately $35,000. Values First Advisors Inc. purchased a new position in shares of Celcuity in the third quarter worth $86,000. SG Americas Securities LLC bought a new stake in Celcuity during the 3rd quarter valued at $119,000. Finally, Bleakley Financial Group LLC purchased a new stake in Celcuity during the 4th quarter valued at $146,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.